Date:8/3/2009

slates foreign currency sales and expenses to dollars at the weighted average of exchange rates in effect during the period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.

    CONTACT:   Investors                       Media
               EVC Group                       EVC Group
               Douglas Sherk, 415-896-6820     Christopher Gale 646-201-5431
               Michael Pollock, 415-896-5862

    (Tables to Follow)



    STAAR Surgical Company
    Condensed Consolidated Statements of Operations
    (In 000's except for per share data)
    Unaudited

                                                  Three Months Ended
                                                  ------------------
                                           % of    July 3,    % of   June 27,
                                           sales    2009     sales     2008
                         
'/>"/>
SOURCE  STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth